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SecretaseThe neuropathological hallmarks of Alzheimer's disease include extracellular neuritic plaques and neuroﬁbrillary
tangles. The neuritic plaques contain β-amyloid peptides (Aβ peptides) as the major proteinaceous constituent
and are surrounded by activated microglia and astrocytes as well as dystrophic neurites. N-terminally truncated
forms of Aβ peptides are highly prevalent in neuritic plaques, including Aβ 3-x beginning at Glu eventually
modiﬁed to pyroglutamate (Aβ N3pE-x), Aβ 2-x, Aβ 4-x, and Aβ 5-x. The precise origin of the different
N-terminally modiﬁed Aβ peptides currently remains unknown. To assess the contribution of speciﬁc cell
types to the formation of different N-terminally truncated Aβ peptides, supernatants from serum-free primary
cell cultures of chicken neurons, astrocytes, and microglia, as well as human astrocytes, were analyzed by
Aβ-ELISA and one- and two-dimensional SDS-urea polyacrylamide gel electrophoresis followed by immunoblot
analysis. To evaluate the contribution of β- and γ-secretase to the generation of N-terminally modiﬁed Aβ,
cultured astrocytes were treated with membrane-anchored “tripartite β-secretase (BACE1) inhibitors” and the
γ-secretase inhibitor DAPT. Neurons, astrocytes, and microglia each exhibited cell type-speciﬁc patterns of
secreted Aβ peptides. Neurons predominantly secreted Aβ peptides that begin at Asp1, whereas those released
from astrocytes and microglia included high proportions of N-terminally modiﬁed Aβ peptides, presumably
including Aβ 2/3-x and 4/5-x. The inhibition of BACE1 reduced the amount of Aβ 1-x in cell culture supernatants
but not the amount of Aβ 2-x.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Alzheimer's disease (AD) is the most common neurodegenerative
disorder in the elderly and is characterized by the neuropathological
hallmarks of synaptic and neuronal loss, neuritic plaques, and neuroﬁ-
brillary tangles (NFT) that consist of hyperphosphorylated tau protein
(Glenner and Wong, 1984; Masters et al., 1985; Delacourte and
Defossez, 1986; Grundke-Iqbal et al., 1986). The extracellular plaques
in AD-brain parenchyma are primarily composed of β-amyloid peptides
(Aβ peptides), of which a large proportion is N-terminally truncated.
(Glenner and Wong, 1984; Masters et al., 1985; Miller et al., 1993;
Saido et al., 1995; Kuo et al., 2001; Sergeant et al., 2003; Guntert et al.,
2006; Schieb et al., 2011; Moore et al., 2012; Bayer and Wirths, 2014).nd Psychotherapy, University of
gen, Germany. Fax: +49 9131
aler).
ect.com).
. This is an open access article underIn particular, Aβ peptides beginning at Glu3, which is eventually modi-
ﬁed to pyroglutamate (AβN3pE-x), and Aβ beginning at Phe4 appear to
be highly abundant. Other reported N-terminally truncated Aβ-variants
include Aβ starting at Ala2 and Arg5. Aβ peptides are ubiquitously
generated from the amyloid precursor protein (APP) as products of
physiological cellular metabolism and can be detected in cell culture
supernatant, cerebrospinal ﬂuid (CSF), and human blood plasma
(Haass et al., 1991; Haass and Selkoe, 1993; Wang et al., 1996;
Wiltfang et al., 2002; Maler et al., 2007). The pivotal enzyme that
exhibits β-secretase activity is BACE1, which is a transmembrane
aspartyl protease that cleaves APP between Met671 and Asp672 and
between Tyr681 and Glu682 (numbering according to APP770)
(Hussain et al., 1999; Vassar et al., 1999; Lee et al., 2003). Recent ﬁnd-
ings suggest that other enzymes, including glutaminyl cyclase, cathep-
sin B, meprin, neprilysin, myelin basic protein, plasmin, angiotensin-
converting enzyme, and aminopeptidases, may compete with or act in
concert with BACE1 to produce several N-terminal variants of Aβ
peptides (Howell et al., 1995; Saido, 1998; Van Nostrand and Porter,the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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2008; Liao et al., 2009; Sevalle et al., 2009; Bien et al., 2012; Bayer and
Wirths, 2014). The subsequent proteolytic cleavage that generates the
C-terminus of Aβ is accomplished by γ-secretase, which is a multien-
zyme complex consisting of presenilin, nicastrin, anterior pharynx de-
fective 1a or 1b, and presenilin enhancer 2 (De Strooper, 2003). Aβ
peptides with different C-termini are released from cells because cleav-
age by γ-secretase can occur at multiple sites of the APP fragment
(Struhl and Adachi, 2000; Wiltfang et al., 2002). Variations in the
amino acid sequence of Aβ in terms of different N- andC-termini greatly
affect their propensity to form oligomers, insoluble protoﬁbrils, ﬁbrils,
and, ultimately, Aβ plaques (Thal et al., 2006). In particular, Aβ peptides
ending at Ala42 and carrying a truncated N-terminus (e.g., Aβ (pGlu3-
42) and Aβ 4-42) appear to be highly prone to aggregation (Bouter
et al., 2013). For Aβ N3pE-42 an increased tau-dependent neuronal
death has been demonstrated in comparison to Aβ 1-42 alone in cell
culture (Nussbaum et al., 2012). Additionally an association between
Aβ NpE-x and hyperphosphorylated tau was demonstrated in human
brain tissue and the severity of AD neuropathology correlated with
frontal NpE-Aβ load, indicating a potential role of this N-terminal
truncated Aβ for the initiation and progress of AD (Mandler et al., 2014).
In cell culture supernatant, CSF, and blood plasma, the most abun-
dant Aβ peptide variant is Aβ 1-40 (Wang et al., 1996; Vandermeeren
et al., 2001; Esselmann et al., 2004; Maler et al., 2007; Haussmann
et al., 2013). CSF predominantly contains Aβ peptides that begin at
Asp1; in human blood plasma, a high proportion of N-terminally modi-
ﬁed Aβ peptides has been detected (Lewczuk et al., 2004; Maler et al.,
2007). In the Aβ plaques associated with AD, Aβ peptides that end at
Ala42 (Aβ x-42) are highly prevalent, and the N-terminus exhibits
substantial heterogeneity (Sergeant et al., 2003; Rufenacht et al.,
2005; Guntert et al., 2006; Thal et al., 2006). Aβ N3pE-x, Aβ N11pE-x,
and Aβ 1-x that contain an N-terminal isoaspartate are frequently
observed in neuritic plaques (Saido et al., 1996). The percentage of
N-terminally truncated Aβ peptides, particularly N3pE-x, Aβ 2-x, Aβ
4-x, and Aβ 5-x, in neuritic plaques appears to increase with disease
progression and to be associated with Braak stage of AD-related NFT/
neuropil thread (NT) pathology (Braak and Braak, 1991; Braak et al.,
2006; Guntert et al., 2006). The Aβ plaques associated with AD are
typically composed of a thioﬂavin S positive, dense-core plaque
surrounded by reactive astrocytes that express GFAP, interdigitating
microglia, and dystrophic neurites (neuritic plaques) with abnormal
tau protein (Selkoe, 2001; Thal et al., 2006). Thioﬂavin S negative,
diffuse plaques can be abundant in brains of non-demented elderly and
commonly are nonneuritic and not associated with glial activation.
Based on observations from cell culture models and relative BACE1
expression levels, neurons have been suggested to be the major source
of Aβ peptides in the brain (LeBlanc et al., 1997; Vassar et al., 1999; Lee
et al., 2003). Because of their potential phagocytic activity, microglia and
astrocytes were hypothesized to participate in the removal of Aβ plaques
(Thal et al., 2006). However, microglia and astrocytes appear to also pro-
duce small quantities of Aβ peptides (Haass et al., 1991; LeBlanc et al.,
1996, 1997). The contribution of each cell type to the production of differ-
ent variants of Aβ peptides has not yet been addressed.
To assess whether the heterogeneity of N-terminally modiﬁed Aβ
peptides may be explained by different cell type-speciﬁc proﬁles of
secreted Aβ peptide variants, we established primary chicken cell
culture models of neurons, astrocytes, and microglia and examined
the Aβ peptide variants released into the cell culture supernatants
using ELISA and one- and two-dimensional urea-SDS-PAGE. The chick
embryo has previously been described as a suitablemodel for investiga-
tions in the processing of APP. The C-terminal APP domain in chicken is
highly homologous to human APP, the amino acid sequence is identical
to that in humans, and it expresses BACE-1, BACE-2, presenilin-1,
presenilin-2 and nicastrin (Carrodeguas et al., 2005). To investigate
potential species differenceswith respect to theAβpattern, the secreted
Aβ peptide variants from cultivated human astrocytes were examined.Furthermore, we evaluated the inﬂuence of BACE1 and γ-secretase
inhibition on the secretion of N-terminally modiﬁed Aβ peptide
variants.
Material and methods
Isolation, culture, and characterization of primary cells
FertilizedWhite Leghorn SPF eggs were obtained from Charles River
Laboratories (Sulzfeld, Germany). Primary neuronal cultures were
derived from the telencephali of 8-day-old chick embryos, and cells
were cultivated in serum-free Neurobasal-ATM containing B27 supple-
ment (Gibco, Eggenstein, Germany) at a cell density of 3.75 ∗ 105 cells/
cm2, as previously described (Esselmann et al., 2004). Experiments
were performed after the 5th day in vitro (div).
The cells were characterized bymorphology and immunocytochem-
istry using the following primary antibodies: rabbit anti-tau polyclonal
antibody (pAb) (1:500; DAKO, Hamburg, Germany), mouse anti-GFAP
monoclonal antibody (mAb) (clone GA5, 1:500; DAKO, Hamburg,
Germany), mouse anti-ﬁbronectin mAb (clone FN-15, 1:500; Sigma-
Aldrich, München, Germany), mouse anti-MOSP mAb (clone 328,
1:500; Chemicon, Temecula, CA, USA), and mouse anti-vimentin mAb
(clone Vim 13.2, 1:500; Sigma Aldrich, München, Germany). For immu-
nocytochemistry, cells were ﬁxed with 0.4% w/v paraformaldehyde in
PBS at room temperature (RT) for 7 min. Roti®-ImmunoBlock (Carl
Roth, Karlsruhe, Germany) containing 0.1% v/v Triton X-100 was used
as a blocking agent. Following incubation with primary antibodies,
goat anti-mouse and goat anti-rabbit Abs labeled with Alexa Fluor®
488 (1:1000; Invitrogen, Darmstadt, Germany) as well as DAPI were
used for visualization under a Leica DM IL HC Bio ﬂuorescence
microscope.
For the identiﬁcation of microglia, samples were probed with FITC-
BS1-B4 lectin (1:50 in PBS/0.02% sodium azide for 30 min at RT;
Invitrogen, Darmstadt, Germany), Alexa Fluor® 488-AcLDL (1:250 in
cell culture medium for 8 h at 37 °C; Invitrogen, Darmstadt,
Germany), Alexa Fluor® 488-heat inactivated-E. Coli (1:5000 in cell
culture medium for 8 h at 37 °C; Invitrogen, Darmstadt, Germany),
and Fluoresbrite® Yellow Green beads (1:2000 in cell culture medium
for 8 h at 37 °C; Polysciences Europe GmbH, Eppelheim, Germany)
according to the manufacturer's instructions with the aforementioned
modiﬁcations. After the 5th div, 60% of the cells in neuronal cultures
were tau-positive neurons, and less than 5% of the cells were GFAP-
positive astrocytes and latex bead-phagocytosing microglia. Immuno-
staining using antibodies against vimentin, ﬁbronectin, or MOSP was
negative.
For primary cultures of astrocytes and microglia, telencephali of
16-day-old chick embryos were dissected, homogenized, and resus-
pended in DMEM/10% FBS/1% penicillin/streptomycin. The cells were
seeded at a density of 0.01 brains/cm2. For astroglial cultures, a
complete medium exchange was performed every two days. After
reaching 80% conﬂuence, the astrocytes were passaged and replated at
a cell density of 1.5 ∗ 104 cells/cm2. After the 12th div, the serum-
containing medium was gradually reduced to serum-free DMEM/
Ham's F12 containing 10 mM HEPES and G5 supplement (PAA, Cölbe,
Germany) or Neurobasal-ATM containing B27 supplement within four
days. Experiments were performed after the 16th div. After the 18th
div, over 90% of the cells were positive for vimentin and exhibited a
ﬂat polygonal shape. The cells were only positive for GFAP after incuba-
tion in AM Medium (ScienCell, Carlsbad, CA, USA), indicating a quies-
cent state of the cultivated astrocytes under the aforementioned
culture conditions. Immunostainingwith antibodies against ﬁbronectin,
tau, or MOSP was negative.
For microglial cultures, a complete medium exchange was
performed after the 6th div. After the 12th and 16th div, the culture
medium was centrifuged at 500 g for 5 min to remove dead cells and
was added to the microglial cultures. The cells were maintained in PBS
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detached using Accutase (PAA, Cölbe, Germany) and were replated at
a cell density of 2.5 ∗ 105 cells/cm2 in 80% conditioned medium and
20% serum-free microglial medium containing DMEM, 4.5 g/l glucose,
0.2 mg/ml BSA, 5 μg/ml insulin, 5 μg/ml transferrin, and 5 nM sodium
selenite. After the 25th div, the serum-containingmediumwas gradual-
ly reduced to serum-free microglial mediumwithin two days. After the
27th div, over 90% of the cells inmicroglial cultureswere phagocytosing
cells. Immunostaining with antibodies against tau, GFAP, vimentin,
ﬁbronectin, or MOSP was negative. Experiments were performed after
the 27th div.
Human fetal astrocytes (ScienCell, Carlsbad, CA, USA)were cultivated
according to the manufacturer's instructions. To detect Aβ peptides in
supernatants or cell lysates, serum-containing AMMedium (ScienCell,
Carlsbad, CA, USA) was gradually changed to DMEM/Ham's F12
(Biochrom, Berlin, Germany) containing G5 supplement (PAA,
Germany) and 10mMHEPES (Biochrom, Berlin, Germany). Experiments
were performed between the 5th div and the 32nd div.
Drug treatment and sample preparation
Tripartite compounds and DAPT (N-[N-(3,5-diﬂuorophenacetyl)-
L-alanyl]-S-phenylglycine t-butyl ester) (Sigma-Aldrich, München,
Germany) were dissolved in DMSO at a concentration of 2 mM and
10 mM, respectively, and stored at −20 °C. The tripartite BACE1
inhibitors used in this study, which are designated as “BACE-I53”
and “BACE-I89” and correspond to compounds 8e and 8g, respective-
ly, were previously described in detail (Schieb et al., 2010). A
complete medium exchange was performed prior to treatment, and
medium with drugs diluted in DMSO or medium with DMSO alone
was added to the cells, yielding the maximum ﬁnal concentration
of 0.1% v/v DMSO. For the analysis of Aβ peptides in unstimulated
cell culture supernatants, a complete medium exchange was
performed; neuronal cultures were incubated for 24 h, astrocyte
cultures were incubated for 24 h or 48 h, and microglial cultures
were incubated for 96 h. Cells treated with tripartite BACE1 inhibi-
tors and DAPT were incubated for 24 h and 48 h, respectively. Subse-
quently, the cell culture supernatants were centrifuged at 500 g for
5 min and stored at −20 °C. Cells were washed with PBS for 5 min
and lysed in detergent buffer (50 mM HEPES, 0.037 w/v Complete
Mini Protease Inhibitor Cocktail (Roche, Grenzach-Wyhlen,
Germany), 150 mM NaCl, 1% v/v NP-40, 0.5% w/v NaDOC, and
0.1% w/v SDS) for 15 min at 4 °C. The lysed cells were centrifuged
(13,000 g, 5 min, 4 °C), and supernatants were stored at −20 °C.
The pellets were resolubilized with shaking in 70% v/v formic acid
for 10 min at RT. Formic acid was evaporated in a vacuum concentra-
tor. To evaluate the extracellular degradation of Aβ peptides, condi-
tioned media from chicken astrocytes were incubated at 37 °C and
5% CO2 for 7 days in polypropylene reaction tubes to minimize the
loss of Aβ peptides that results from their adsorption to polystyrene
surfaces. Each experiment was repeated at least three times in
quadruplicate.
Cell viability assays
Cell viability was assessed after drug treatment using the CytoTox
96® lactate dehydrogenase assay (Promega, Madison, CA, USA) accord-
ing to the manufacturer's instructions and the MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, as previously
described (Mosmann, 1983).
Immunoprecipitation of Aβ peptides
For the immunoprecipitation of Aβ peptides, 40 μg/ml 1E8 mAb
(nanoTools, Teningen, Germany) or 6E10mAb (Covance, San Francisco,
CA, USA) was covalently coupled to 10 mg/ml magnetic sheep anti-mouse Dynabeads M-280 (Dynal, Hamburg, Germany) according to
the manufacturer's instructions.
The quadruplicate samples were pooled and subsequently mixed
with ﬁve-fold concentrated detergent buffer containing either 20 μl
or 25 μl of magnetic beads coupled with 1E8 mAb or 6E10 mAb,
respectively, yielding ﬁnal concentrations of 0.8 μg/ml of immobilized
1E8 mAb and 1 μg/ml of immobilized 6E10 mAb in 50 mM HEPES,
150 mM NaCl, 0.5% v/v Nonidet P-40, 0.25% w/v sodium deoxycholate,
and 0.05% w/v SDS. For the immunoprecipitation of pooled cell
lysates, the samples were dissolved in detergent buffer yielding ﬁnal
concentrations of 0.8 μg/ml of immobilized 1E8 mAb in 50 mM HEPES,
150 mM NaCl, 1% v/v Nonidet P-40, 0.5% w/v sodium deoxycholate,
and 0.1% w/v SDS. Immunoprecipitation was performed under rotation
for 15 h at 4 °C. Subsequently, the sampleswere rinsed three timeswith
PBS/0.1% BSA for 5 min at 4 °C and once with 10 mM Tris-HCl, pH 7.5.
For 1D-Aβ-PAGE, rinsed Aβ-coupled magnetic particles were heated
to 95 °C in sample buffer (0.36 M Bis–Tris, 0.16 M Bicine, 15% w/v su-
crose, 1% w/v SDS, and 0.0075% w/v bromphenol blue). For 2D-Aβ-
PAGE, the Aβ peptides were eluted as previously described (Maler
et al., 2008).
BCA assay
The concentration of total protein in cell lysates was determined
using the BCA assay as previously described (Smith et al., 1985). The
absorption at 562 nm was measured using a Benchmark Microplate
Reader (Bio-Rad, München, Germany) and was quantiﬁed using
Microplate Manager 5.1 software (Bio-Rad, München, Germany).
1D-Aβ-IPG-urea-SDS-PAGE
The eluted protein samples and synthetic Aβ peptides (Aβ 1-38/40/
42 (Bachem, Bubendorf, Schweiz); Aβ 1-37/39 (Biosynthan, Berlin,
Germany); Aβ 2-40/42 and Aβ 3-40/42 (MoBiTec, Rastatt, Germany);
Aβ N3pE-40/42 (MoBiTec, Rastatt, Germany); and Aβ 4/5-42(MoBiTec,
Rastatt, Germany)) in sample buffer were separated using urea-Bicine/
Bis–Tris/Tris/sulfate SDS-PAGE (1D-Aβ-PAGE) as previously described
(Klafki et al., 1996; Wiltfang et al., 1997).
2D-Aβ-IPG-urea-SDS-PAGE
High-resolution two-dimensional electrophoresis of Aβ (2D-Aβ-
PAGE) using immobilized pH gradients (IPGs) was performed as pre-
viously described (Maler et al., 2007). The samples eluted in rehy-
dration buffer (8.3 M urea, 2% w/v CHAPS, 0.5% v/v pharmalyte
pH 3–10, and 20 mM DTT) or synthetic Aβ peptides in rehydration
buffer were incubated with IPG DryStrip gels (7 cm, nonlinear pH
range of 3–10 or linear pH range of 4–7) over 10 h at 20 °C. Isoelec-
tric focusing was performed using an Ettan IPGphor II IEF System
(GE Healthcare, München, Germany). After equilibration of focused
IPG strips in equilibration buffer (6 M urea, 0.36 M Bis–Tris, 0.16 M
Bicine, 2% w/v SDS, and 20% w/v glycerol) for 10 min with 1% w/v
DTT followed by an additional equilibration for 10 min with 4.8%
w/v iodoacetamide at RT, the proteins were separated in the second
dimension as previously described.
Western blot and immunodetection (2D-IB)
Aβ peptides were detected by immunoblot analysis under semidry
conditions (Hoefer Semi-Phor) using a discontinuous buffer system as
previously described (Maler et al., 2007). Brieﬂy, the peptides were
transferred onto a PVDFmembrane (Immobilon,Millipore, Schwalbach,
Germany) at 1 mA/cm2 for 45 min. The PVDF membranes were subse-
quently boiled for 3 min for optimal antibody detection and blocked
for 2 h at RT in Roti®-Block (Carl Roth, Karlsruhe, Germany) for immu-
nostaining using the 1E8 mAb (nanoTools, Teningen, Germany) or the
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6E10 mAb (Covance, San Francisco, CA, USA) or the N3pE mAb (IBL,
Hamburg, Germany), membranes were blocked with PBS-T/2% w/v
ECL Prime Blocking Reagent (GE Healthcare, München, Germany). The
blots were probed with the 1E8 mAb (1:300 in Roti®-Block), the 6E10
mAb (1:1000 in PBS-T/2% ECL Prime Blocking Reagent), the 82E1 mAb
(1:1000 in Roti®-Block), or the N3pE pAb (1 μg/ml in PBS-T/2% ECL
Prime Blocking Reagent) at 4 °C overnight. Themembraneswere rinsed
three times with PBS/0.075% v/v Tween (PBS-T) and incubated with
biotinylated goat anti-mouse IgG (333 ng/ml in PBS-T; Vector Laborato-
ries Ltd., Peterborough, United Kingdom) or with peroxidase-
conjugated horse anti-rabbit IgG (Calbiochem, Frankfurt, Germany)
for 60 min at RT. Subsequently, the PVDF membranes that were probed
with biotinylated goat anti-mouse IgG were rinsed in PBS-T and incu-
bated with streptavidin–horseradish peroxidase complex (1:3000 in
PBS-T; Amersham Pharmacia, Germany). Finally, all of the PVDF
membranes were rinsed again in PBS-T, and detection was performed
using ECL Prime Western Blotting Detection Reagent (GE Healthcare,
München, Germany) and a Fluor-S MAX MultiImager (Bio-Rad,
München, Germany) according to the manufacturer's instructions. Pro-
tein bands and spots detected after 1D-Aβ-PAGE/IB and 2D-Aβ-PAGE/IB
analysis were quantiﬁed using TotalLab Quant v1.1.4301.25363
(totallab, Jahnsdorf, Germany) as previously described (Maler et al.,
2007).
Aβ-ELISA
The concentrations of Aβ 1-42, Aβ 1-40, and Aβ N3pE-40 were
studied with commercially available ELISA kits from Innogenetics
(Ghent, Belgium) and IBL (Hamburg, Germany), respectively. The
dilutions, incubations, and washings steps were performed according
to the manufacturer's recommendations and were applied in CSF
analyses, but the samples were diluted 1:20 or 1:80 rather than 1:400
for the analysis of Aβ 1-40. The concentrations of Aβ x-42 and Aβ
x-40 were analyzed using a multiplex assay (Innogenetics, Ghent,
Belgium) in the Luminex platform as previously described (Lewczuk
et al., 2010), but the sample dilutions were adjusted for the cell culture
supernatants. All of the measurements were performed in duplicate.
Statistical analysis
The data were analyzed using GraphPad Prism version 6.02
(GraphPad Software, San Diego, CA, USA) and SPSS Statistics version
22.0 (IBM, San Jose, CA, USA). Differences between groups were deter-
mined using the unpaired t-test, Wilcoxon matched-pair signed-rank
test, the Kruskal–Wallis test followed by Dunn's multiple comparisons,
one-way analysis of variance (ANOVA) followed by Dunnett's multipleFig. 1.Quantiﬁcation of Aβ 1-40 in the supernatants of cultured neurons and astrocytes with EL
of Aβ 1-40 secreted by chicken neurons and astrocyteswithin 24 hwas determined using ELISA
x-42/Aβ x-40 that were assessed using a multiplex immunoassay were similar between astroccomparisons test, or multivariate analysis of variance (MANOVA)
followed by Dunnett's T3 correction as a post-hoc test when a signiﬁ-
cant effectwas observed. All data are expressed as themean± standard
deviation (SD). Signiﬁcance levels are indicated as follows: ***p b 0.001;
**p b 0.01; *p b 0.05; and ns, not signiﬁcant.
Results
Astrocytes and microglia produced a higher proportion of N-terminally
truncated Aβ than neurons
To estimate the amount of Aβ 1-40 secreted by neurons and astro-
cytes, Aβ peptides in cell culture supernatants were ﬁrst assessed
using ELISA, and the values were normalized to the amount of total
cellular protein as determined using the BCA assay (Fig. 1). The quantity
of Aβ 1-40 detected in the supernatants of astrocyte cultures after 24 h
of incubation was 1.5 ± 0.3 ng per mg of total cellular protein. In
contrast, neuronal cultures released approximately sevenfold more Aβ
than astrocytes, i.e., 10.3±2.5 ngof Aβ 1-40 permg of total cellular pro-
tein. The concentrations of Aβ 1-42 and Aβ N3pE-42 were below the
limits of detection of the respective ELISA kits. For evaluation of the
Aβ42/40 ratios a multiplex immunoassay was employed. Although the
total amount of Aβ peptides in cell culture supernatantswas signiﬁcant-
ly different between astrocytes and neurons, the Aβ42/Aβ40 ratios in
neuronal and astrocyte cell culture supernatants determined using a
multiplex immunoassay did not signiﬁcantly differ, indicating a similar
pattern of γ-secretase cleavage in both cell types. The quantities of Aβ
x-40 and Aβ x-42 as assessed by the multiplex immunoassay are
shown in the supporting information (Supporting information Fig. S1).
To assess the secretion of additional Aβ peptide variants, includ-
ing Aβ peptides that possess different N-termini, semiquantitative
1D-Aβ-PAGE followed by immunoblot (IB) analysis (1D-Aβ-PAGE/
IB) was performed. 1D-Aβ-PAGE/IB revealed signiﬁcantly higher
proportions of Aβ that comigrated with Aβ 2-40 in the supernatants
from astrocytes in comparison to those in the supernatants from
neurons and even higher proportions of the presumed Aβ 2-40 in
the supernatants of microglia (Fig. 2). Consistent with the ELISA
results (see above), the Aβ 1-42/Aβ 1-40 ratios of astrocytes and
neurons were not signiﬁcantly different. Collectively, these results
indicate that predominantly N-terminally truncated Aβ peptides
may be released in a cell type-speciﬁc manner.
The majority of Aβ released by astrocytes or microglia were N-terminally
modiﬁed
To further characterize the observed Aβ peptides (in addition to an
increased resolution and the ability to detect possible additionalISA and determination of the Aβ42/Aβ42 ratios withmultiplex immunoassay. The amount
(unpaired t-test; **p b 0.01) (A). Despite the differences in these amounts, the ratios of Aβ
ytes and neurons (Mann–Whitney U test; ns: not signiﬁcant) (B).
Fig. 2.QuantiﬁcationofAβ1-x andAβ2-x in the supernatants of culturedneurons, astrocytes,
andmicroglia using 1D-Aβ-PAGE/IB analysis. Aβpeptides secreted by chicken neurons, astro-
cytes, andmicrogliawithin 24h, 48 h, and 96h in 0.8ml, 1.6ml, and 2.4ml of sample volume,
respectively, were immunoprecipitated with the 1E8 mAb (0.8 μg/ml). Subsequently, the
immunoprecipitated Aβ peptides and a sample of synthetic Aβ peptides (S.) were loaded,
separated, andvisualized in1D-Aβ-PAGE/IBusing the 1E8mAb (A). The identities of the load-
ed synthetic Aβ peptides are indicated on the left. The different Aβ peptide bandswere quan-
tiﬁed and identiﬁed using a dilution series of synthetic Aβ. The most abundant band was Aβ
1-40, independent from the cell type used. The ratio of Aβ 1-42/Aβ 1-40was not signiﬁcantly
different between the supernatants of neurons and astrocytes (Kruskal–Wallis test followed
by Dunn's multiple comparisons; ns: not signiﬁcant) (B). The ratio of Aβ 2-40/Aβ 1-40 was
signiﬁcantly elevated in samples of astrocytes and microglia in comparison to neurons
(Kruskal–Wallis test followed by Dunn's multiple comparisons; ns: not signiﬁcant;
*p b 0.05; and ***p b 0.001) (C). Each experiment was performed at least three times.
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indicate N-terminal truncation or elongation), the supernatants of neu-
rons, astrocytes, and microglia were analyzed using 2D-Aβ-PAGE
followed by immunoblot (2D-IB) analysis. A panel of different antibod-
ies against the N-terminal region of Aβ was employed to characterize
the observed charged Aβ variants. The monoclonal antibody 82E1 is
speciﬁc for peptides that begin at Asp1 (Aβ 1-x), whereas the
1E8 mAb recognizes the Aβ 1-x and Aβ 2-x. Moreover, the 6E10 mAb
detects several N-terminally truncated Aβ peptides that begin at Asp1,
Ala2, Glu3, Phe4, or Arg5 (n-x) (Fig. S2 in the Supporting information
and Lewczuk et al. (2010)).
The supernatants of astrocytes and microglia exhibited higher
proportions of chargedAβ variantswith pI values N5.4 than the superna-
tants of neurons, and these variants presumably correspond to Aβ 2-x,
Aβ 3-x, Aβ 4-x, and Aβ 5-x (Fig. 3).
In 2D-IB analysis probed with the 1E8 mAb, the ratios of Aβ 2-40
exhibiting a pI of 6.4 to Aβ 1-40 (pI of ~5.4)were approximately tenfold
higher in the supernatants from astrocytes or microglia than from
neurons. In addition to Aβ 2-x and Aβ 3-x, which exhibited pI values
of 6.4, astrocytic and microglial supernatants contained additional
charged Aβ variants exhibiting pI values of approximately 5.0, 5.5, and
5.7. These variants were minimally detected in neuronal cell culture
supernatants (Fig. 3). In 2D-IB analysis probed with the 6E10 mAb,
additional Aβ variants were detected at pH 7.0, which presumably
corresponded to Aβ 4-x and/or Aβ 5-x. The ratio of Aβ peptides that
exhibited pI values of 7.0 to Aβ 1-40 was also more than tenfold elevat-
ed in the supernatants of astrocytes compared to neurons (Fig. 3 and
Table S1 in the Supporting information).
MANOVA was conducted to determine whether the proﬁles of
secreted charged Aβ variants differed among neurons, astrocytes, and
microglia (Fig. 4). The results of this analysis indicated, that each cell
exhibited an individual pattern of Aβ variants with different pI values.
In general, astrocytes and microglia secreted a signiﬁcantly higher
proportion of Aβ peptides that exhibited a pI greater than 5.4 in com-
parison to neurons, indicating N-terminal truncations or possibly
other modiﬁcations.
In contrast to the vast differences in the proportions of N-terminally
truncated Aβ peptides among neurons, astrocytes, and microglia, the
proportions of Aβ 1-37, Aβ 1-38, Aβ 1-39, and Aβ 1-42 (pI of 5.4) to
Aβ 1-40 did not differ and resembled the distribution of the correspond-
ing Aβ peptides in human CSF and blood plasma (Fig. 3 and Table S1 in
the Supporting information). In all of the investigated cell culture
models, Aβ 1-40 was the most abundant Aβ variant, which exhibited a
pI of 5.4, followed by Aβ 1-38 and Aβ 1-42 (Table S1 in the Supporting
information).
In cell culture supernatants from astrocytes, but not from neurons or
microglia, an Aβ peptide exhibiting a pI of 6.4 was reproducibly detect-
ed in 2D-IB analysis using the 82E1mAb (Fig. 3). This antibody is specif-
ic for Aβ peptides that begin at Asp1. Therefore, this particular Aβ
variant appears to begin at Asp1 and has presumably acquired an addi-
tional positive charge or lost a negative charge due to a non-identiﬁed
posttranslational modiﬁcation.
Collectively, approximately more than 80% of all detected Aβ vari-
ants thatwere secreted by neurons began at Asp1, whereas themajority
of Aβ peptides released by astrocytes and microglia were N-terminally
truncated or otherwise modiﬁed, and less than 40% of all detected Aβ
peptides were Aβ 1-x in the supernatants of astrocytes (Table S1 in
the Supporting information). Aβ N3pE-x was not observed in 2D-IB
analysis of the supernatants of astrocytes or neurons. In contrast,
synthetic Aβ 3-40, Aβ 3-42, Aβ N3pE-40, and Aβ N3pE-42 (100 pg of
each) were equally detected in 1D-IB and 2D-IB analyses probed with
the 6E10 mAb (data not shown). Extended incubation times (24 h or
48 h) or the use of a different cell culture medium (serum-free
DMEM/F12 containing HEPES and G5 supplement, NbA, or AM) did
not inﬂuence the pattern of secreted astroglial Aβ peptides when
assessed using 2D-Aβ-PAGE/IB analysis probed with the 1E8 mAb. To
Fig. 3. The pattern of N-terminally modiﬁed Aβ variants in the supernatants of cultured chicken neurons, astrocytes, and microglia. Supernatants from serum-free cultures of chicken
neurons, astrocytes, and microglia were obtained after 24 h, 48 h, and 96 h, respectively. Aβ from 1.8 ml (A, D), 2.4 ml (B, E, G), and 4.0 ml (C, F, H) sample volumes, respectively,
were immunoprecipitated with the 1E8 mAb (0.8 μg/ml; A-F) or the 6E10 mAb (1.0 μg/ml) (G, H). Subsequently, the immunoprecipitated Aβ peptides were dissolved, separated, and
visualized by 2D-Aβ-PAGE/IB using IPG strips in a linear pH range of 4–7 (A–F) or a nonlinear pH range of 3–10 (G, H). Representative 2D-Aβ immunoblots (2D-IB) from samples of neu-
rons (A, D, G), astrocytes (B, E, H) andmicroglia (C, F) that were probed using the Aβ 1-x-speciﬁc 82E1mAb (A-C), the Aβ 1-x- andAβ 2-x-speciﬁc 1E8mAb (D–F), and the Aβ n-x-speciﬁc
6E10mAb (G, H) are shown. The sequence of Aβ and the epitopes of the differentmAbs are shown (J). In 2D-IB analysis using the 82E1mAb, a series of spots at a pI of 5.4 corresponding to
Aβ1-40 and additional Aβ 1-x variants was observed in all examined samples (A–C). An additional single 82E1 mAb-positive spot, which presumably corresponds to a modiﬁed Aβ 1-x
(identiﬁed as Aβ 1*-x), was detected at a pI of 6.4 only in samples obtained from astrocytes (B). In 2D-IB analysis using the 1E8mAb (D–F), an additional series of spots was observed at pI
values of 5.0, 5.5, 5.7, and 6.4. These spots wereminimally detected in neuronal samples (D) but were abundant in samples from astrocytes (E) andmicroglia (F). 2D-IB analysis using the
6E10mAb revealed an additional series of spots at a pI of 7.0, whereas all of the remaining spots corresponded to those detected in 2D-IB analysis using the 1E8mAb. The proposed iden-
tities of the marked spots and their observed pI values are presented in (I) based on comigration of synthetic Ab peptides (Fig. S2) and mass spectrometry data as previously reported
(Schieb et al., 2011). All of the experiments were performed at least three times (nl = nonlinear; and mAb= monoclonal antibody).
29T.J. Oberstein et al. / Neurobiology of Disease 73 (2015) 24–35investigate the extent of the extracellular degradation of Aβ peptides,
conditioned supernatants of astrocytes in the absence or presence of
protease inhibitors were incubated for 7 days at 37 °C. The amount of
Aβ 1-40 in the conditioned media in the absence of protease inhibitors
was reduced to 65± 24% in comparison to samples supplemented with
protease inhibitors, which indicates a slow degradation of Aβ peptides
by secreted extracellular proteases (Fig. S3 in the Supporting informa-
tion). The relative proportions of the remaining Aβ peptide variants
were not different between samples with or without added protease
inhibitors.Cultured human astrocytes secreted a similar pattern of N-terminally
truncated Aβ peptides as chicken astrocytes
Because different species may exhibit a different pattern of secreted
Aβ peptides, the Aβ proﬁle in the supernatants of cultivated human
astrocytes was determined using 2D-Aβ-PAGE/IB analysis (Fig. 5). The
relative abundance of the presumed N-terminally truncated Aβ 2/3-x
and 4/5-x (pI ~6.4 and ~7.0) in cell culture supernatants of human
andchicken astrocyteswas very similar.Mann–WhitneyU test indicated
no signiﬁcant differences for Aβwith pI 6.4 (Fig. 5). Chicken and human
Fig. 4. Comparison of charged Aβ variants in the supernatants of cultured chicken neurons, astrocytes, and microglia by 2D-Aβ-PAGE/IB. Means and standard deviations of the ratios
between the sum of all Aβ variants exhibiting an identical pI (i.e., 5.0, 5.5, 5.7, 6.4, or 7.0) and Aβ 1-40 in 2D-Aβ-PAGE/IB are shown. A MANOVAwas conducted using cell type (neurons,
astrocytes, and microglia) as the independent variable and four ratios of charged Aβ variants (the sum of all Aβ variants exhibiting pI values of 6.4, 5.7, 5.5, or 5.0 to Aβ 1-40) as the
dependent variables to determine whether neurons, astrocytes, and microglia were distinguishable by their proﬁle of secreted Aβ peptides that exhibit different pI values. MANOVA,
based on data from 2D-Aβ-PAGE/IB analysis using the 1E8 mAb (A), revealed a signiﬁcant multivariate main effect for cell type (Wilks' λ= 0.092; F = 8.600; p b 0.001; and partial
eta squared = 0.696). Signiﬁcance levels of post-hoc tests (Dunnett's T3 correction) are shown (A). Astrocytes and microglia secreted a higher proportion of Aβ peptides with pI values
of 6.4, 5.0, and 5.7 than neurons. There was no difference between astrocytes and microglia. The relative abundance of Aβ peptides exhibiting a pI of 5.5 from microglia signiﬁcantly
exceeded the relative abundance of these peptides from neurons and astrocytes. MANOVA based on data from 2D-Aβ-PAGE/IB analysis using the 6E10mAb (B) conﬁrmed that astrocytes
andmicrogliawere distinguishable by their proﬁle of secretedAβ peptides (Wilks'λ= 0.203; F= 7.087; p b 0.01; and partial eta squared= 0.797). Signiﬁcance levels of univariatemain
effects are shown (B) (ns: not signiﬁcant; *p b 0.05; **p b 0.01; and ***p b 0.001). Each experiment was performed at least three times.
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values of approximately 5.0, 5.5, and 5.7. Consistent with the results
from avian cultures, the spot corresponding to Aβ 1-40 that exhibited
a pI of 5.4 in 2D-IB analysis of human astrocytes was the most intense
followed by spots corresponding to Aβ 1-39 and Aβ 1-42 (Table S2 in
the Supporting information).
Small amounts of Aβ 1-x were detected in cell lysates
To investigate whether the N-terminally truncated Aβ peptides
originated from intracellular compartments, detergent-soluble and
formic acid-soluble cell fractions were analyzed. In contrast to the ﬁnd-
ings from the analysis of cell culture supernatants, N-terminally truncat-
ed Aβ peptides were not observed in cell lysates of astrocytes and
microglia by 2D-IB analysis using the 1E8 mAb (Fig. 6). In all of the
detergent-soluble fractions from neurons, astrocytes, and microglia,
Aβ 1-x variants that exhibited a pI of 5.4were nearly exclusively detect-
ed. The scarce amount of intracellular Aβ peptides in microglia
corresponded to the low concentrations of Aβ peptides in the cell
culture supernatants. A comparison of the intracellular and extracellular
proportions of Aβ peptides exhibiting a pI of 5.4 indicated an elevated
ratio of intracellular Aβ 1-42/Aβ 1-40 in comparison to extracellular
Aβ 1-42/Aβ 1-40, particularly in astrocytes. The high variability of Aβ
1-42 could be due to extraction variability of this peptide. The ratios of
Aβ 1-39/Aβ 1-40, Aβ 1-38/Aβ 1-40, and Aβ 1-37/Aβ 1-40 were not
signiﬁcantly different between intracellular lysates and extracellular
supernatants (Fig. 6 and Table S3 in the Supporting information).
Formic acid extractions of detergent-insoluble cell fractions did not
yield additional Aβ peptides.
The inhibition of γ-secretase with DAPT reduced the secretion of all N- and
C-terminal Aβ variants
To investigate whether the differences between intracellular and
extracellular Aβ proﬁles of astrocytes were related to possible differ-
ences in the secretase pathways, the effects of β- and γ-secretase inhib-
itors were examined. In astroglial cultures treated with the γ-secretase
inhibitor DAPT for 48 h, the amount of all of the detected Aβ 1-x and
N-terminally modiﬁed Aβ was reduced in a dose-dependent fashion
as indicated by 1D-IB analysis (Figs. 7A and B). The secretion of thepresumed N-terminally truncated Aβ 2-40 and Aβ 1-40 uniformly de-
creased, indicating that N-terminally modiﬁed Aβ peptides and Aβ 1-x
both rely on γ-secretase cleavage. In astrocyte cultures, 10 μM DAPT
reduced the amount of secreted Aβ 1-40 to 7.1 ± 3.4% in comparison
to unstimulated controls. Concentrations below 25 μM DAPT were not
cytotoxic according to LDH measurements or the reduction of cell
viability, as assessed using the MTT assay (data not shown).
The secretion of N-terminally modiﬁed Aβ peptides remained unaffected or
increased upon BACE inhibition
Membrane-anchored “tripartite BACE inhibitors” were used to
inhibit BACE in astrocyte cultures. The “tripartite structure” consisted
of the peptidic BACE inhibitor “GL189” (Tung et al., 2002) that was
linked via a 53 Å (BACE-I53) or an 89 Å (BACE-I89) spacer to a
dihydrocholesterol anchor (Linning et al., 2012). As expected, the total
amount of Aβ peptides released into the cell culture supernatants was
substantially reduced in thepresence of 25 or 500 nMtripartite BACE in-
hibitor. In astrocyte cultures treated with BACE-I53, the amount of
released Aβ 1-40 signiﬁcantly decreased to 12.2 ± 5.3% of the controls.
Interestingly, neither BACE-I53 nor BACE-I89 had statistically signiﬁcant
effects on the abundance of speciﬁc Aβ peptide bands comigrating with
Aβ 2-40 compared to controls in 1D-IB (Figs. 7C–E).
Concentrations of 500 nM BACE-I53 were not cytotoxic according to
LDH measurements and did not reduce cell viability, as assessed using
the MTT assay (data not shown).
Discussion
The present study compares the proﬁles of Aβ peptide variants of
primary neurons, astrocytes, and microglia. Of particular interest was
the generation of N-terminally modiﬁed Aβ peptides. Speciﬁc
N-terminally truncated Aβ peptides, such as NpE 3-x and Aβ 2-x, 3-x,
4-x and 5-x are prevalent in neuritic plaques and appear to increase
with the Braak stage of AD-related NFT/NT pathology. Their precise or-
igin has not yet been identiﬁed unequivocally (Saido et al., 1995;
Sergeant et al., 2003; Guntert et al., 2006). Our results demonstrate
that, in cell culture supernatants of astrocytes and microglia,
N-terminally modiﬁed Aβ presumably corresponding to Aβ 2/3 and
4/5-x are highly prevalent and accounted for more than 60% of the
Fig. 5. The pattern of Aβ peptide variants in the supernatants of cultured human astrocytes. Cultured human astrocytes were incubated for 48 h with serum-free cell culture medium. Aβ
peptides from a sample volume of 3.2 ml (A, B) and 4 ml (C) were immunoprecipitated with the 1E8 mAb (A, B) or 6E10 mAb (C). 2D-Aβ-PAGE/IB was performed as described in Fig. 3.
Representative 2D-IB analyses were probed with the 82E1 mAb (A), 1E8 mAb (B), and 6E10 mAb (C). The distribution of spots in supernatants of human astrocytes corresponded to the
distribution of spots in samples of chicken astrocytes at pH values of 5.4, 6.4, and 7.0. The relative intensities of Aβ peptides exhibiting a pI of 6.4 were not signiﬁcantly different between
human and chicken astrocytes in 2D-IB analysis using the 1E8 mAb (Mann–Whitney U test; ns: not signiﬁcant) (D). The spots with pI values of 5.0, 5.5, and 5.7 were also observed in
human astrocytes but exhibited different relative abundance in comparison to chicken astrocytes. Each experiment was performed at least three times. The proposed identities of the
marked spots and their observed pI values are presented in (E).
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and only small amounts of N-terminally modiﬁed Aβ peptides.
Pyroglutamate-modiﬁed Aβ peptides such as NpE x-3 were not
detected in the cell culture models used here. The relative abundance
patterns of Aβ peptides in supernatants from primary astrocytes
from humans were found to be very similar to those from the chick
embryo. Importantly, the highly reproducible pattern of secreted
Aβ peptides in astrocyte cultures was independent not only of
species but also of the incubation period and the cell culture medi-
um. A relatively high proportion of N-terminally modiﬁed Aβ
peptides was also observed in the supernatant of cultured chicken
microglia that closely resembled the pattern of secreted Aβ peptides
from untransfected human phagocytes (Maler et al., 2008). The
2D-Aβ-PAGE/IB method employed here allows for a direct compari-
son of the relative abundances of several Aβ peptide variants differ-
ing in charge and electrophoretic mobility in the presence of SDS and
urea. However a limitation of this study is that the exact identities of
some of the detected peptides remain to be elucidated by mass
spectrometry.
To the best of our knowledge, the relative abundance patterns of
monomeric Aβ variants secreted by untransfected primary neurons,
astrocytes, and microglia have not been published before. Previous
studies either compared the amount of total Aβ peptides of thesecell types or addressed Aβ variants in cell culture supernatants of
transfected cell lines overexpressing wild-type or mutant APP,
e.g., N2a/APP695, 7PA2/APP751:V717I, H4/APP695:K670M/N671L, and
SH-SY5Y/APP695 (Haass and Selkoe, 1993; LeBlanc et al., 1996; Wang
et al., 1996; Vandermeeren et al., 2001; Haussmann et al., 2013;
Portelius et al., 2013). The most abundant Aβ peptides identiﬁed in
these cell models were Aβ variants that begin at Asp1. Additionally,
N-terminally truncated Aβ peptides, i.e., Aβ 2-x, Aβ 3-x, Aβ 4-x, and
Aβ 5-x, were also detected in small amounts using mass spectrometry
or immunoblot analysis (Wang et al., 1996; Haussmann et al., 2013).
However, the relative proportions of the N-terminally truncated Aβ
peptides that are released from transfected cells are difﬁcult to compare
with the present results because the overexpression of APP may affect
the subcellular distribution and metabolism of APP. Furthermore the
cell lines may have lost speciﬁc physiological functions during their
immortalization. A limitation of all these and similar studies, including
our present one, is that the pattern of Aβ peptides secreted from
cultured cells does not necessarily reﬂect the generation of Aβ peptides
in the aged human brain especially under disease conditions. The
contribution of individual cells to the formation of N-terminal truncated
Aβ in vivo remains to be addressed in further studies. The secretion of
N-terminal truncated Aβ by neurons might outweigh the contribution
of glial cells just because of the larger amount of total Ab secreted by
Fig. 6. The pattern of Aβ variants in lysed cell fractions of cultured neurons, astrocytes, andmicroglia. Detergent-soluble cell fractions of neurons (A), astrocytes (B), andmicroglia (C)were
immunoprecipitated using the 1E8 mAb and analyzed by 2D-Aβ-PAGE/IB. Representative 2D-IB are shown, that were probed with the 1E8 mAb. Only spots with a pI of 5.4, which pre-
sumably corresponded to Aβ 1-x, were detected in samples of neurons (A) and microglia (C). In contrast, cell lysates of astrocytes contained a very faint additional peptide exhibiting a
pI of 6.4, which shows the same electrophoretic properties as Aβ 1*-x that was observed in the cell culture supernatants of astrocytes. Other N-terminally modiﬁed Aβ peptides were
not detected in 2D-Aβ-PAGE/IB analysis of cell lysates probed with the 1E8 mAb. MANOVA was conducted to determine whether the ratios of the intracellular Aβ peptides,
e.g., Aβ 1-42/Aβ 1-40, Aβ 1-39/Aβ 1-40, Aβ 1-38/Aβ 1-40, and Aβ 1-37/Aβ 1-40,were different from the corresponding ratios of extracellular Aβ peptides in the supernatants. A signiﬁcant
multivariate main effect was detected in astrocytes (MANOVA; Wilks' λ = 0.107; F = 16.731; p b 0.001; and partial eta squared = 0.893) but not in neurons (MANOVA; Wilks'
λ= 0.671; F= 0.367; ns; and partial eta squared= 0.329). Signiﬁcant univariate main effects indicated that the ratio of Aβ 1-42/Aβ 1-40 was signiﬁcantly higher in intracellular lysates
than in extracellular supernatants of astrocytes (**pb 0.01) (E). For the remaining ratios of intracellular Aβ peptides, no signiﬁcant univariatemain effectswere observed. Each experiment
was performed at least three times. The proposed identities of the marked spots and their observed pI values are presented in (F).
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number of glial cells has been reported to be higher than the number
of neurons in the human cerebral cortex (Herculano-Houzel, 2014).
Secreted extracellular proteases appear to have onlyminimal impact
on the Aβ proﬁles in cell culture supernatants. Only ~35% of Aβ 1-40 in
conditioned cell culture media was found to be degraded within seven
days at 37 °C. Additionally, the ratios of the remaining N-terminally
modiﬁed Aβ peptides, presumably corresponding to Ab 2-x, to total
Aβ peptides were not signiﬁcantly altered after this incubation period,
indicating that exopeptidases present in the cell culture supernatant
did notmediate the N-terminal truncation of these Aβ peptides. Consis-
tent with these results, a lack of degradation of Aβ peptides was report-
ed upon the addition of synthetic Aβ peptides to the medium of N2a/
APP695 cells (Wang et al., 1996). The fragments of Aβ peptides cleaved
by extracellular proteases were shown to be primarily generated by
cleavage near the middle or near the C-terminus of Aβ (Wang et al.,
1996). Some studies suggested that Aβ-degrading enzymes were
released into the cell culture medium, but the majority of Aβ-
degrading enzymes appear to be associated with the plasmamembrane
or intracellular (Qiu et al., 1998; Saido and Iwata, 2006; Pacheco-Quinto
and Eckman, 2013).Collectively, culturedmicroglia and astrocytes produce substantially
less total Aβ than neurons but a relatively higher proportion of speciﬁc
N-terminally truncated Aβ variants. These ﬁndings may be relevant for
the development and progression of the amyloid pathology observed in
AD brains. This hypothesis is consistent with histological examinations
that have demonstrated increased numbers of reactive astrocytes near
Aβ plaques that contain N-terminally truncated Aβ peptides (Thal
et al., 2006). Furthermore there are implications from a transgenic
mouse model (PS1ΔE9ﬂox mice), that cells other than excitatory
neurons can give rise age-dependently to amyloid plaques
(Veeraraghavalu et al., 2014). On the other hand in APP/PS1KI mice, in
which human APP 751 carrying the London (V717I) and the Swedish
(K670N/M671L) mutation was under the control of the neuronal thy-
1 promoter, N-terminal truncated Aβ peptides were detected corre-
sponding to the age of mice, which suggests that under these circum-
stances neurons may be the major source for N-terminal truncated Aβ
(Casas et al., 2004). Yet, a glial origin of the of N-terminal truncated
Aβ in this model cannot be fully excluded, as long-term primary
cultures and cultures using tissue from older animals demonstrate
that thy-l does appear on some astrocytes later in development
(Pruss, 1979).
Fig. 7. Effects of the inhibition ofγ-secretase and BACEon the pattern of Aβ peptides in the supernatants of cultured astrocytes. Supernatants from cultured chicken astrocytes treatedwith
the γ-secretase inhibitor DAPT or a tripartite BACE inhibitor were analyzed by 1D-PAGE/IB. A) Representative 1D-IB analysis of cell culture supernatants of astrocytes treated with 0.1%
DMSO (vehicle alone) and 1 μM, and 10 μMDAPT for 48 h. For comparison, a sample of synthetic Aβ peptides, as indicated on the left of each 1D-IB (S.), was loaded. The blot was probed
with the 1E8 mAb. All of the detected Aβ-peptides were substantially reduced after treatment with the γ-secretase inhibitor. B) Dose response curves for selected Aβ-variants indicated
statistically signiﬁcant reductions of Aβ1-40 and Aβ2-40 as compared to vehicle controls (DMSO). The mean relative band intensities and standard deviations are shown. Dose–response
experiments were analyzed by one-way ANOVA followed by Dunnet's post hoc test with DMSO treated astrocytes as control group. Signiﬁcance levels of post hoc tests are shown
(*p b 0.05; **p b 0.01; ***p b 0.001; ****p b 0.0001). C) Representative 1D-IB analysis of cell culture supernatants of astrocytes treated with the tripartite BACE-inhibitor BACE-I53 or ve-
hicle alone (DMSO). While Aβ1-40was clearly reduced by BACE-I53, speciﬁc other Aβ-variants were not. D) Dose response curves for selected Aβ-peptides 1-40 and 2-40 indicated a sta-
tistically signiﬁcant reduction of Aβ1-40 but not of Aβ2-40. Similarly treatment with BACE-I89 reduced Aβ1-40 signiﬁcantly, while other Aβ-variants were not affected (E, F). All
experiments were performed at least three times.
33T.J. Oberstein et al. / Neurobiology of Disease 73 (2015) 24–35Intracellular N-terminally truncated Aβ peptides, presumably
corresponding to Ab 2-x, were not detected in 2D-Aβ-PAGE/IB
analysis from primary chicken neurons, astrocytes, and microglia.
Only Aβ peptides exhibiting identical electrophoretic properties as
extracellular Aβ peptides that begin at Asp1 were detected. The
relative abundance of intracellular Aβ 1-42 was slightly elevated
in comparison to the relative abundance of the corresponding extra-
cellular peptide. Elevated amounts of intracellular Aβ 1-42, particu-
larly in astrocytes, have been previously reported (Nagele et al.,
2003). In comparison to human AD brain extracts, which typically
contain higher amounts of Aβ 1-42 than Aβ 1-40 especially, in de-
tergent soluble fractions from astrocytes the amount of Aβ 1-40
exceeded the amount of Aβ 1-42 similarly as observed in cell culture
supernatant, human CSF and blood plasma. It appears that in the
AD-brain, Aβ42 is preferentially deposited during disease onset
and progression reﬂecting its reported higher propensity to aggre-
gate in vitro (Jarrett et al., 1993; Harper et al., 1997).
The proportions of the remaining intracellular Aβ peptides and their
corresponding extracellular Aβ peptides, i.e., Aβ 1-37, Aβ 1-38, and Aβ
1-39, were similar. This result indicates that, in our study, neurons,
astrocytes, and microglia did not take up and accumulate the secreted
N-terminally truncated Aβ peptides, presumably corresponding toAb 2-x, to a measurable extent. It has been previously suggested that
the intracellular pool of Aβ peptides of cultured SH-SY5Y cells does
not consist of phagocytosed Aβ peptides (Pacheco-Quinto and Eckman,
2013). In contrast, astrocytes and microglia appear to be capable of
phagocytosing extracellular Aβ peptides of amyloid plaques because
in histological preparations, astrocytes in the vicinity of amyloid plaques
were positive for Aβ N3pE-x (De Kimpe et al., 2013). Enhanced phago-
cytosis or generation of intracellular N-terminally truncated Aβ by
astrocytes could be triggered by changes of activities and expression
levels of enzymes, including glutaminyl cyclase, which was reported
to be involved in the formation of Aβ N3pE-x (Cynis et al., 2006;
Schilling et al., 2008). In our cell culture model the absence of distinct
intracellular N-terminally modiﬁed Aβ peptides and the ineffective
generation of N-terminally truncated Aβ peptides by secreted extracel-
lular proteases may be due to a different origin and metabolism of Aβ
1-x compared to Aβ 2-x.
Interestingly, in addition to the previously described Aβ 1-x, a pep-
tide that was only observed in astrocyte supernatants and cell lysates
was detected using the 82E1 mAb, which is speciﬁc for Aβ peptides
that begin at Asp1. However, in contrast to the detected Aβ 1-x variant
(pI of 5.4), this peptide exhibited a pI of 6.4, indicating that this pre-
sumed Aβ 1-x posttranslationally lost an acidicmodiﬁcation or acquired
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this peptide remain to be elucidated.
The N-terminally modiﬁed Aβ peptides, presumably corresponding
to Ab 2-x, were secreted by astrocytes in the presence of effective
concentrations of membrane-targeted tripartite BACE inhibitors while
Aβ 1-x variants were reduced as expected.
BACE plays a pivotal role in the production of Aβ peptides from APP,
particularly in primary neurons and cell lines transfected with APP
(Vassar et al., 1999; Lee et al., 2003). N-terminally truncated Aβ
peptides have been previously suggested to be generated by aminopep-
tidases following the primary cleavage of APP by BACE (Saido, 1998;
Sevalle et al., 2009). In contrast, our results indicate that BACE inhibition
speciﬁcally reduced the secretion of Aβ 1-x in astrocyte cultures,where-
as the amount of Aβ 2-x typically found in astrocytes remained
unaltered or was even increased. These ﬁndings are consistent with
previous reports indicating that treatmentwith BACE inhibitors reduces
the amount of Aβ 1-x in the supernatant from APP-transfected cells, the
CSF of dogs, and in neuronal cultures and causes a concomitant
increased release of N-terminally truncated Aβ peptides, such as Aβ
5-40 (Schieb et al., 2011; Mattsson et al., 2012; Haussmann et al.,
2013). Studies from BACE knockout mice revealed that primary cortical
cells still produced small amounts of Aβ peptides despite abolished
BACE (Roberds et al., 2001). These ﬁndingsmight indicate the existence
of proteases in addition to BACE1 that are presumably responsible for
the de novo generation of N-terminally modiﬁed Aβ peptides. A poten-
tial candidate protease that has been shown to be capable of producing
Aβ 2-x is meprin β (Bien et al., 2012). In contrast to BACE1, meprin
appears to preferentially cleave APP at the plasma membrane. APP
cleavage at the cell surface may explain our observations that Aβ 2-x
was not intracellularly detected in cell samples from primary neurons,
astrocytes, and microglia. Another candidate for an alternative
β-secretase is cathepsin B, which was detected in microglia and astro-
cytes and exhibits an unspeciﬁc cleavage pattern at the N-terminus of
the Aβ sequence (Takeda et al., 2004; Hook et al., 2005; Bohme et al.,
2008; Sun et al., 2008). In particular, Aβ 5-x appears to be generated
by cathepsin B in SH-SY5Y and HEK293 cells (Takeda et al., 2004).
Other studies suggested that cathepsin B may contribute to a
C-terminal truncation of Aβ 1-42, thereby generating Aβ 1-38 and Aβ
1-33 (Sun et al., 2008).
Conclusion
Collectively, different cell types may genuinely exhibit or modulate
the activity and expression of different proteases capable of cleaving
APP at or close to the β-secretase site, which may explain the observed
cell type speciﬁc differences in the patterns of secreted Aβ peptides. Our
results indicate that astrocytes and microglia, but not neurons, secrete
proportionally high amounts N-terminally modiﬁed Aβ peptides,
among others Aβ 2-x, and that the release of Aβ 2-x appears to be
independent of BACE1 itself. We speculate that the high prevalence of
N-terminally modiﬁed Aβ peptides, especially Aβ 2-x, in formic acid
soluble extracts from AD plaques may originate from glial rather than
neuronal cells, thereby providing a novel perspective on the role of
glial cells in AD pathology.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2014.08.031.
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